ALLO vs. INDV, OCUL, CALT, AMPH, ARDX, DYN, AUPH, SNDX, BGM, and ADPT
Should you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Indivior (INDV), Ocular Therapeutix (OCUL), Calliditas Therapeutics AB (publ) (CALT), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Dyne Therapeutics (DYN), Aurinia Pharmaceuticals (AUPH), Syndax Pharmaceuticals (SNDX), Qilian International Holding Group (BGM), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry.
Allogene Therapeutics vs.
Indivior (NASDAQ:INDV) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, community ranking, valuation, risk and institutional ownership.
Indivior currently has a consensus price target of $15.00, suggesting a potential upside of 39.41%. Allogene Therapeutics has a consensus price target of $9.29, suggesting a potential upside of 491.65%. Given Allogene Therapeutics' higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Indivior.
Allogene Therapeutics received 273 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 65.89% of users gave Allogene Therapeutics an outperform vote.
In the previous week, Indivior had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 9 mentions for Indivior and 8 mentions for Allogene Therapeutics. Indivior's average media sentiment score of 1.16 beat Allogene Therapeutics' score of 0.68 indicating that Indivior is being referred to more favorably in the media.
Indivior has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.
Indivior has higher revenue and earnings than Allogene Therapeutics. Indivior is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
Allogene Therapeutics has a net margin of 0.00% compared to Indivior's net margin of -3.96%. Allogene Therapeutics' return on equity of -52.13% beat Indivior's return on equity.
60.3% of Indivior shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 24.3% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Allogene Therapeutics beats Indivior on 10 of the 19 factors compared between the two stocks.
Get Allogene Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allogene Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALLO) was last updated on 4/25/2025 by MarketBeat.com Staff
Buy ALLO Stock Free ALLO Stock Alerts